Generalizability of the REDUCE-IT Trial in Patients With Stable Coronary Artery Disease

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

ELSEVIER SCIENCE INC

1. Servier
2. Amarin Pharma
3. Abbott
4. Daiichi-Sankyo
5. Boehringer Ingelheim
6. Bayer
7. Amarin
8. Amgen
9. AstraZeneca
10. Bristol-Myers Squibb
11. Chiesi
12. Eisai
13. Ethicon
14. Forest Laboratories
15. Idorsia
16. Ironwood
17. Ischemix
18. Lilly
19. Medtronic
20. PhaseBio
21. Pfizer
22. Regeneron
23. Roche
24. Sanofi
25. Synaptic
26. The Medicines Company
27. Servier International